J Oral Med Oral Surg
Volume 25, Number 2, 2019
|Number of page(s)||2|
|Section||Cas clinique / Short case report|
|Published online||26 March 2019|
Short Case Report
Nivolumab-induced oral and cutaneous bullous pemphigoid: A case report
Odontology Department, Pellegrin Hospital, Bordeaux, France
2 Dermatology Department, Pellegrin Hospital, Bordeaux, France
* Corresponding author: email@example.com
Accepted: 11 January 2019
Introduction: Nivolumab-induced oral and cutaneous bullous pemphigoid have been rarely reported in the literature. Observations: A 64-year-old male patient was treated with nivolumab for melanoma. He presented with oral lesions in the palatal and gingival mucosal lesions. Nine months after the initiation of nivolumab therapy, a cutaneous bullous pemphigoid was found on his right forearm. The level of anti-BPAG2 (or anti-BP 180) was positive with a rate of 83 AU/mL, thereby confirming the diagnosis of bullous pemphigoid. His oral mucosa, first in the posterolateral area of the palate and then in the gingiva, was affected 3 months later. Histological examination revealed a subepidermal bulla with few eosinophils. Comments: Nivolumab is a novel monoclonal human antibody used to potentiate T cell responses, particularly anti-tumor responses. The first diagnosis considered was lichen planus, and it has been excluded from this study based on histological results. Right from lesion onset after treatment initiation, nivolumab was strongly suspected to cause these mucocutaneous lesions. To investigate the causes and effects of nivolumab-induced oral and cutaneous bullous pemphigoid, it would be necessary to record the regression of these lesions at the end of treatment; however, this is not possible due to ethical reasons. The treatment of lesions primarily involves corticosteroid usage; however, rituximab is also used. Conclusion: Oral surgeons must consider the oral side effects of novel targeted therapies, including those of immunological checkpoint inhibitors.
Key words: pemphigoid / bullous / nivolumab / mouth
© The authors, 2019
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.